Dose-escalated CHOEP for the treatment of young patients with aggressive non-Hodgkin's lymphoma: I. A randomized dose escalation and feasibility study with bi- and tri-weekly regimens

Annals of Oncology

Volumn 19, Issue 3, 2008, Pages 538-544

  Trumper L ^a   Zwick, C ^b   Ziepert, M ^c   Hohloch, K ^a   Schmits, R ^b   Mohren, M ^d   Liersch, R ^e   Bentz, M ^f   Graeven, U ^g   Wruck, U ^h   Hoffmann, M ⁱ   Metzner, B ^j   Hasenclever, D ^c   Loeffler, M ^c   Pfreundschuh, M ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d Hospital Magdeburg   (Germany)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f City Hospital of Karlsruhe   (Germany)

^g KLINIKEN MARIA HILF GMBH   (Germany)

^h Helios Kliniken   (Germany)

ⁱ Städtische Kliniken Ludwigshafen   (Germany)

^j KLINIKUM OLDENBURG   (Germany)

more..

Author keywords

Aggressive NHL; Chemotherapy models; Clinical trials; Dose escalation

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; EVENT FREE SURVIVAL; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 40149094020     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm497     Document Type: Article

References (16)

1. M. Pfreundschuh L. Trumper M. Kloess Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL Blood 104 2004 626 633
2. M. Pfreundschuh L. Truemper A. Oesterborg CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the Mabthera International Trial (MInT) Group Lancet Oncol 7 2006 379 391
3. R.M. Meyer W.M. Hryniuk M.D. Goodyear The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma J Clin Oncol 9 1991 339 347
4. D. Hasenclever O. Brosteanu T. Gerike Modelling of chemotherapy: the effective dose approach Ann Hematol 80 2001 B89 B94
5. N.L. Harris E.S. Jaffe J. Diebold World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997 J Clin Oncol 17 1999 3835 3849
6. The International Non-Hodgkin's Lymphoma Prognostic Factors Project A predictive model for aggressive non-Hodgkin's lymphoma N Engl J Med 329 1993 987 994
7. B.E. Storer Design and analysis of phase I clinical trials Biometrics 45 1989 925 937
8. H. Tesch V. Diehl B. Lathan Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group Blood 92 1998 4560 4567
9. J. O'Quigley M. Pepe L. Fisher Continual reassessment method: a practical design for phase 1 clinical trials in cancer Biometrics 46 1990 33 48
10. B.D. Cheson S.J. Horning B. Coiffier Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1999 1244
11. E.M. McKelvey J.A. Gottlieb H.E. Wilson Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma Cancer 38 1976 1484 1493
12. H. Tilly N. Mounier P. Lederlin Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte J Clin Oncol 18 2000 1309 1315
13. M.A. Shipp D. Neuberg M. Janicek High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study J Clin Oncol 13 1995 2916 2923
14. J.H. Goldie A.J. Coldman A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate Cancer Treat Rep 63 1979 1727 1733
15. H.E. Skipper F.M. Schabel Jr Spontaneous AK leukemia (lymphoma) as a model for human leukemias and lymphomas Cancer Chemother Rep 3 3 1972 3 5
16. L. Norton R. Simon Tumor size, sensitivity to therapy, and design of treatment schedules Cancer Treat Rep 61 1977 1307 1317